The Bacterial Vaccines Network (BactiVac) announced today that it has received £1 million ($1.2 million US) from UK-based charitable organization Wellcome to accelerate the development of bacterial vaccines.
Based at the University of Birmingham, BactiVac brings together more than 1,400 members in the academic, industry, and policy sectors from 78 countries to advance the development of vaccines targeting the bacterial pathogens of global importance. Over half of its members are from low- and middle-income countries (LMICs), which have been disproportionately affected by bacterial infections and antimicrobial resistance (AMR).
Since its founding in 2017, the network has focused on raising awareness of the need for bacterial vaccines, promoting interaction and collaboration among members, and providing catalyst funding for new research projects. BactiVac Co-director Adam Cunningham, PhD, said in a press release that the funding will enable the network to build on those efforts over the next 4 years.
BactiVac will continue to support its membership to develop new vaccines, particularly those that are relevant to LMICs.
"We are grateful to Wellcome for their generous support and for sharing BactiVac’s vision that bacterial vaccines have a critical role to play in reducing bacterial infections and the threat of AMR," he said. "In this exciting new phase, BactiVac will continue to support its membership to develop new vaccines, particularly those that are relevant to LMICs."
In a July 2022 report, the World Health Organization said that with the current antibiotic pipeline relatively short on new candidates, vaccines have become a "highly attractive" tool that could help curb AMR by reducing the incidence of bacterial infections and reducing the overall use and misuse of antibiotics.